Taysha Gene Therapies Announces Participation in Upcoming March Investor Healthcare Conferences

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced its upcoming participation in virtual fireside chats at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, at 1:50 pm ET, and at Stifel’s 3^rd Annual CNS Day on March 31, 2021, at 10:30 am ET. Both events will feature RA Session II, President, Founder and CEO. Audio webcasts will be available in the “Events & Media” section of Taysha's corporate website for 60 days after the events.

Positive

• Participation in significant industry conferences enhances visibility and credibility.
• Opportunity to showcase advancements in AAV gene therapy pipeline.

Negative

• None.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31^st Annual Healthcare Conference and Stifel’s 3^rd Annual CNS Day.

Conferences Details:

Event: Oppenheimer 31^st Annual Healthcare Conference (Virtual)
Date: Tuesday, March 16, 2021
Time: 1:50 pm ET
Format: Fireside chat
Participants: RA Session II, President, Founder and CEO

Event: Stifel’s 3^rd Annual CNS Day (Virtual)
Date: Wednesday, March 31, 2021
Time: 10:30 am ET
Format: Fireside chat
Participants: RA Session II, President, Founder and CEO

Audio webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005331/en/

FAQ

What events is Taysha Gene Therapies participating in March 2021?

Taysha is participating in the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, and Stifel’s 3^rd Annual CNS Day on March 31, 2021.

Who will represent Taysha Gene Therapies at the conferences?

RA Session II, President, Founder and CEO, will represent Taysha at both conferences.

Where can I find the audio webcasts of Taysha's conference presentations?

Audio webcasts will be available in the “Events & Media” section of Taysha's corporate website.

How long will the webcasts from Taysha's conferences be available?

The archived webcasts will be available on Taysha's website for 60 days after the events.